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Abstract 
OBJECTIVES: Health Related Quality of Life (HRQoL) data generated by generic, 
preference-based instruments (i.e. EQ-5D) are highly demanded in health policy decision-
making, because they allow for direct comparisons of HRQoL outcomes between disease 
areas. We aimed to quantify HRQoL outcomes in Breast Cancer (BC), Rheumatoid Arthritis 
(RA), Multiple Sclerosis (MS), Rare Cancers (RC) and Rare Disease (RD) patients and 
understand the patterns that differentiate HRQoL outcomes between these disease areas, and 
more specifically between rare and more common disease population groups. METHODS: 
An international, web-survey of patients measured HRQoL (EQ-5D-5L), self-perceived 
health (EQ-5D-5L Visual Analogue Scale) and additional QoL dimensions such as patient 
disability level. RESULTS: We received 675 completed responses. Average utility loss was 
53.5%, 32.5% and 33.3% for RD, RA and MS patients respectively, in contrast to 18.6% for 
BC and RC patients. Statistically significant differences (p<0.05) were observed between 
disease groups in all EQ-5D-5L domain outcomes, apart from that of "Anxiety/Depression". 
Severe and/or extreme problems were reported in performing usual activities for RD and RC 
(34% and 13% of overall problems reported respectively), mobility for MS (18%), 
pain/discomfort for RA (13%) and anxiety/depression for BC (7%) patients. 
CONCLUSIONS: We demonstrated significant differences in the dimensions that drive 
HRQoL outcomes between rare and more common diseases and showcased that the same 
EQ-5D utility may reflect very different severities depending on the patient population under 
investigation. Future research should examine whether outcomes in other, critical HRQoL 
domains not included in generic measures also highlight significant differences across disease 
areas. 
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Background 
The health-related quality of life (HRQoL) of individuals suffering from a chronic condition 
is often significantly impaired and this is a key concern not only for patients, their caregivers 
and clinicians but also for healthcare policy makers [1]. Chronic disorders often present with 
high socio-economic burden either due to increased mortality (i.e. malignant neoplasms being 
the second leading cause of death [2]), to long-term disability (i.e. in rheumatic disorders and 
multiple sclerosis [3]), or to high unmet treatment needs (i.e. in rare disorders, where 
treatment is available only for 5% of the approximately 7,000 rare diseases discovered [4]). 
While numerous studies have addressed the impact of chronic diseases and their treatment on 
HRQoL outcomes literature is still unclear about the specific dimensions of Quality of Life 
(QoL) that are impaired by different chronic disorders, as well as the extent to which the level 
of impairment on these dimensions varies between patient populations of different chronic 
disorders [1]. There have been very few comparisons on the impact of different chronic 
disorders on QoL, and even more scarce are comparisons of QoL outcomes between rare and 
more common disease areas [5,6]. Such comparisons are key in HRQoL research for chronic 
diseases since they contribute in understanding the drivers of poor outcomes in one disease 
area relative to another and therefore facilitate decisions on the cost-effective allocation of 
resources for research, health care services use and disease management across diseases [1].  
In order to perform such comparisons of patient outcomes within and between disease areas, 
HRQoL data generated by preference based HRQoL measurement instruments are highly 
demanded in health policy decision making. One of the most widely used preference based 
instruments intended to measure and value health outcomes across a wide range of diseases 
and treatments is the five-dimension EuroQol (EQ-5D), which has been certified in many 
countries worldwide; it is commonly used in economic evaluation and technology assessment 
[7, 8] and as a standard tool in clinical studies because of its generic nature.  
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Very few studies have used generic, preference based HRQoL measurement tools, namely 
the SF-24 [9] and the SF-36 [1] to compare outcomes between therapeutic areas but these are 
now out-dated and more importantly, due to their heterogeneity with respect to sample 
composition, sample size, instruments and procedures, it was concluded that further empirical 
data is needed to corroborate their findings [9]. In order to increase the body of evidence in 
HRQoL comparisons across chronic diseases, the aim of this paper is twofold; first to  
quantify health state utility outcomes across selected disease areas, namely Breast Cancer 
(BC), Rare Cancers (RC), Multiple Sclerosis (MS), Rheumatoid Arthritis (RA) and RD, and 
second to understand the patterns that differentiate HRQoL outcomes (using the five-
dimension EuroQol (EQ-5D) between disease categories, within their respective disease 
clusters, between disease clusters and more specifically between rare and more common 
disease population groups.  
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Methods  
Sample and Research design  
We conducted a retrospective, web-based survey of individuals with BC, RA, MS, RC and 
RD. Disease areas were selected such that they reflect a significant burden to the society but 
are also represent areas where EQ-5D is commonly used, such that their clinical changes are 
considered to be well reflected in the EQ-5D-5L instrument and used in clinical areas [10].  
Participants were identified through a network of patients and patient associations 
representatives, hosted by the Medical Technology Research Group at the London School of 
Economics (LSE). The survey was based on a multidimensional questionnaire comprising 
three sections which captured; a) patient demographic information and clinically relevant 
characteristics such as disease area and years since diagnosis, b) HRQoL, measured with the 
EuroQol 5-domain 5-level (EQ-5D-5L) instrument, self-perceived health (using the EQ-5D-
5L VAS instrument) and c) additional dimensions related to Quality of Life (QoL) outcomes 
such as patients' physical disability (using the Barthel Index (BI) score). Questionnaires were 
made available in six languages: English, German, Greek, French, Italian and Swedish. 
One hundred and eighty patient associations across 48 countries, primarily from Europe but 
also from Australia, Brazil, China, Indonesia, Japan, Malaysia, Kyrgyzstan, Philippines, 
Singapore and USA were invited via e-mail to voluntarily share the questionnaire with their 
network of patients. Associations representing the following disease areas were invited: BC 
(e.g. Europa Donna), RA (e.g. European League Against Rheumatism - EULAR), MS (i.e. 
US National Multiple Sclerosis Society- NMSS), RC (i.e. Myeloma Patients Europe - MPE), 
and RD (e.g. Rare Connect). To ensure anonymity, questionnaire responses carried no 
identification information (name, address/postcode, e-mail or telephone).  
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All patients were informed about the study objectives and the data confidentiality procedures 
in place, and were asked to provide online written informed consent to indicate their 
understanding of the study conditions and their agreement to participate. The study protocol 
was submitted to the LSE Research Ethics Committee and the committee determined that this 
study was exempt from formal human subjects ethics review because the data collected and 
used for analysis were anonymous and carried no identification information. 
Preceding the actual survey questions, an online information sheet not only described the 
objectives of the survey and processes related to data confidentiality, but also provided a brief 
description of the EQ-5D-5L tool and its utilisation in HRQoL measurement. The survey was 
hosted online on Qualtrics® software under an LSE-verified account and remained open 
between June and August 2015.   
Statistical analyses  
The IBM Statistical Package for Social Sciences (SPSS) version 21 was used to generate 
descriptive statistics (mean, median and standard deviation) and assess the statistical 
significance of differences in HRQoL outcomes between disease areas. HSUVs, VAS, and BI 
scores were all treated as continuous variables. These were assessed for normality using the 
Kolmogorov-Smirnov test and were found to deviate significantly from the normal 
distribution (p<0.05). Therefore, non-parametric inferential tests were used, namely the 
Spearmans rank correlation coefficient to measure relationships between the above 
variables, and the Kruskal-Wallis one-way analysis of variance to assess statistical 
significance of HSUV differences between disease groups.  Finally, outcomes in each EQ-
5D-5L domain were treated as ordinal variables and therefore the Mann-Whitney U test was 
used to assess the statistical significance of differences in the EQ-5D-5L domain outcomes 
between disease areas.  
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Information and main variables of interest 
As not all participating countries had available EQ-5D-5L value sets at the time of analysis, 
the EQ-5D-5L Crosswalk Index Value Calculator was used to calculate utility scores based 
on the reported health states [11].  Subsequently, in order to obtain participants utility loss, 
their utility scores were deducted from the general population Health State Utility Value 
(HSUV) of their respective countries of origin (where such a value was available) [12]. For 
participants whose country of origin did not yet have EQ-5D value sets, UK value sets were 
used as a proxy to calculate their utility score and respective utility loss.  
In addition, patients self-perceived QoL was measured using the EQ-5D-5L VAS tool 
consisting of a vertical 20-cm scale rated from 0100, where 0 and 100 reflect the worst and 
the best imaginary health states, respectively [13]; respondents were asked to indicate a point 
on the scale that best represented their self-perceived overall health on the day the 
questionnaire was completed. We also measured disability level using the Barthel Index, a 
commonly used instrument for the evaluation of an individuals dependence level, based 
upon ability to perform 10 basic Activities of Daily Living (ADLs) [14]; a score of 20 shows 
complete independence, with 15-19 indicating mild dependence, 1014 moderate dependence 
and 0-9 complete dependence due to disability. Finally, participants were asked to rate their 
satisfaction with the treatment they had received from the national healthcare system in their 
countries on a scale from 0 (not satisfied at all) to 10 (extremely satisfied).  
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Results  
Sample size and demographics  
Out of 180 patient associations invited in 48 countries, 675 completed questionnaires eligible 
for analysis surveys were received from 32 countries. Countries comprising the largest parts 
of the returned sample included UK (n=351, 52% of all sample), France (n=106, 15.7%), 
USA (n=78, 11.6%) and Romania (n=60, 8.8%).  
In terms of the condition suffered, our sample comprised of MS (n=254, 37.6% of total 
sample), BC (n=179, 26.5%), RD (n=140, 20.7%), RA (n=53, 7.8%) and RC (n=49, 7.2%) 
patients (a detailed list of RD and RC diagnoses is provided in Supplementary Table 1). 
Average patient age was 47 (±12.8) years and the majority of patients were females (85%), 
married/cohabiting (66%) and employed (42%) (Table 1).    
Sample HRQoL  
EQ-5D-5L Utility (HSUV) 
Table 2 describes the main findings related to the HRQoL outcomes of our sample.  Average 
patient HSUV was 0.6 (±0.26), translating into an average health state utility loss of 29.4%, 
when compared to the HSUVs identified for the general population in the study countries. 
Among disease areas, the lowest average HSUV (i.e. 0.46, ±0.31) was reported by RD, 
followed by MS (0.56, ±0.27) and RA (0.58, ±0.2) patient groups (53.5%, 32.5% and 33% 
utility loss respectively), whereas the highest (i.e. 0.7, ±0.18) was observed for both BC and 
RC patient groups (Table 2).   
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A Kruskal-Wallis H test showed that there were statistically significant differences (p<0.001) 
in mean HSUV (
2 
= 76.3) scores among disease areas (Table 2). More precisely, Mann 
Whitney U tests detected statistically significant differences in the HSUV mean rank of RD 
when compared to all other disease groups, namely BC (p<0.001), RC (p<0.001), RA 
(p=0.05) and MS (p<0.05) (Table 3), and of RA and MS when compared to BC (p<0.001 and 
p=0.001 respectively) and RC (p<0.001 and p=0.001 respectively). No statistically significant 
difference was observed in HSUV outcomes between BC and RC (p=0.941) and between MS 
and RA (p=0.776). Finally, floor and ceiling effects existed in our sample (n=24, 3.6% and 
n=29, 4.4% respectively), with lowest (negative) scores being more commonly reported by 
RD (n=12, 9%) and MS (n=11, 4%) patients and perfect health scores primarily observed for 
BC (6%, n=10) patients. 
 
<Table 1 about here> 
 
EQ-5D-5L VAS  
Our sample had an average EQ-5D-5L VAS score of 63 (±22) and this was moderately 
correlated to the EQ-5D-5L utility score (Spearmans rho=0.582, p<0.001). Disease-specific 
EQ-5D-5L VAS outcomes reflected disease-specific EQ-5D-5L outcomes, with RD 
exhibiting the lowest VAS score, followed by MS, RA, RC and BC (Table 2). A Kruskal-
Wallis H test showed that there were statistically significant differences (p< 0.001) in mean 
VAS (
2
 = 39.2) scores among disease areas (Table 2).  
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More precisely, Mann Whitney U tests detected statistically significant differences in the 
VAS mean rank of RD when compared to all other disease groups, namely BC (p<0.001), RC 
(p=0.001), RA (p=0.001) and MS (p<0.001), and of MS when compared to BC (p<0.05).  
Barthel Index 
Half of the respondents (50.5%) reported being independent on all ADLs indicating that, on 
average, our sample was only mildly dependent when it came to carrying out daily activities, 
whereas BC and RC patient groups were independent on all ADLs. A strong correlation was 
found between patient dependence level and the respective HSUV (Spearmans rho=0.591, 
p<0.001). A Kruskal-Wallis H test showed that there were statistically significant differences 
(p< 0.001) in mean BI (
2
 = 118.2) scores among disease areas (Table 2). More precisely, 
Mann Whitney U tests detected statistically significant differences in the BI mean rank of RD 
when compared to all other disease groups, namely BC (p<0.001), RC (p<0.001), RA 
(p<0.05) and MS (p<0.05) and, of RA and MS when compared to all other disease areas, 
namely BC (p<0.001) and RC (p<0.05 and p<0.001 respectively) but not when compared to 
each other (p=0.445). Finally, it was observed that the BI score was the only HRQoL 
characteristic where outcomes between RC and BC had a statistically significant difference 
(p<0.05).  
 
<Table 2 about here> 
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Decomposition of EQ-5D-5L  
Health profiles were examined to assess the proportions of patients across each disease area 
who reported at least some problems at each level on the EQ-5D-5L dimensions (Figure 1).  
Decomposition of the EQ-5D-5L scores showed that overall, QoL problems varied between 
the EQ-5D dimensions and a worsening of HRQoL was brought about by problems of all 
severity levels (slight, moderate, severe, extreme) in the domains of pain/discomfort (82%, 
of which 14% severe/extreme), followed by performing usual activities (75%, of which 
15% severe/extreme), anxiety/depression (70%, of which 10% severe/extreme) and 
mobility (66%, of which 15% severe/extreme). Self-care was the least problematic EQ-5D-
5L domain across all sample and all disease areas (39% of respondents reported problems, of 
which 7% were severe/extreme). 
Additionally, it was observed that EQ-5D-5L domains with the highest percentage of severe 
and/or extreme problems reported in each disease area included; anxiety/depression for BC 
patients (7%), performing usual activities for RD and RC patients (34% and 13% 
respectively), pain/discomfort for RA patients (13%) and mobility for MS (18%) (Figure 1). 
Finally, no statistically significant differences were observed when the outcomes of each 
disease group in the domain of Anxiety/Depression were compared to each other. 
<Figure 1 about here>  
Assessment of disease-specific outcomes within EQ-5D-5L domains showed that RD had the 
highest mean scores (i.e. highest level of problems) in each domain (Table 3) and 
consequently yielded the greatest differences when compared to all other disease areas, 
across all domains.  
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More precisely, it was demonstrated that these differences were all statistically significant 
(either at the 1% or 5% significance level), apart from those between RD and all other disease 
areas in Anxiety/Depression and those between RD and RA in the domains of Self-care 
and Pain/Discomfort (Table 3).  
<Table 3 about here> 
However, with regards to RD patients poorer health outcomes in some domains relative to 
others were observed, with pain/discomfort having the greatest contribution towards 
worsening of QoL compared to the other disease groups studied (32% compared to, for 
example, a range of 4%-13% of severe and/or extreme problems reported by other disease 
groups as shown on Figure 1). 
Following RD, highest overall burden in all domains was observed for RA and MS groups, 
which both yielded statistically significant differences in Mobility (p<0.05 and p<0.001 
respectively), Self-Care (p<0.001), Usual activities (p=0.001 and p<0.001 respectively) 
and Pain/Discomfort (p<0.001) when compared to BC, in Mobility (p<0.05 and p<0.001 
respectively) and Pain/Discomfort (p<0.001) when compared to RC and only in 
Pain/Discomfort (p<0.05) when compared to each other.  
In addition, a statistically significant difference (p<0.001) in mean scores existed between BC 
and RC only in the domain of Self-Care, although discrepancies were observed both in 
terms of severity and amount of problems reported in each EQ-5D-5L domain (Figure 1). For 
example: the domain of Mobility was the second, least problematic domain for both BC 
and RC patients, although the severity level reported by RC patients was higher compared to 
that reported by BC patients (i.e. 2% and 11% severe/extreme problems respectively).  
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Similarly, even though both groups were equally problem free in the domain of Usual 
activities (i.e. 36% of BC and 34% of RC), the severe/extreme problems experienced in this 
domain by RC patients were much higher compared to BC (i.e. 13% compared to 5% 
respectively). On the contrary, in the domain of Anxiety/Depression both groups reported 
similar levels of severe/extreme problems (i.e. 7% for BC and 6% for RC) but overall, only 
27% of BC patients were problem free in this domain compared to 37% of RC patients.  
Discussion 
HRQoL outcomes and differences between disease areas 
In this study we used a preference based HRQoL measurement tool to detect differences on 
HRQoL outcomes for five different diagnoses across three distinct therapeutic areas, namely 
RD, Cancer (including BC and RC) and autoimmune diseases (including RA and MS).   
Previous studies have assessed the patterns that differentiate HRQoL outcomes between the 
general population and patients [15, 16]. However, among patient populations, it is still 
unclear how, the patterns that lead to HRQoL impairment are differentiated between, or even 
within (i.e. in different cancer diagnoses), therapeutic areas. Existing comparisons of HRQoL 
outcomes between disease-specific patient populations are complicated by differences in the 
various study designs and the instruments used for HRQoL measurement.  
Furthermore, some of these studies are primarily focused on mapping outcomes generated by 
disease specific tools on generic measures, such as the EQ-5D. For example, a study on 
HRQoL outcomes between RA, MS and two types of cancer has mapped outcomes of disease 
specific tools on the EQ-5D and demonstrated results comparable to ours across disease 
areas, although as different clinical criteria were measured by each disease-specific tool, 
comparisons of HRQoL outcomes on the same end points were not feasible [17].  
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A further strength of our study is that we assessed the domains that differentiate HRQoL 
outcomes between RD and more common diseases. Various sources in the literature have 
presented the socioeconomic burden of individual RDs and these have demonstrated similarly 
low HSUV index scores [18-20].  However, only a few studies have provided comparisons 
between a range of RD and the general population [21, 22] and these only assessed outcomes 
in a limited number of RD diagnoses compared to ours, whereas only the latter also provided 
comparisons with common chronic diseases [22]. Nevertheless, these studies presented QoL 
outcomes as overall EQ-5D index scores derived from the literature, and therefore direct 
comparisons on the specific EQ-5D dimensions that differentiated HRQoL impairment 
between the disease groups were not provided. Our study being the only one to date to 
provide evidence from such a wide variety of RD diagnoses from an international population, 
contributes significantly to the literature in providing a holistic understanding of the 
dimensions that drive poor HRQoL outcomes in RD sufferers as a distinct therapeutic group. 
Essentially, this allows us to define more accurately those QoL considerations that should 
drive value in the health technology assessments of new therapies targeting rare as opposed 
to more common disease areas.  Furthermore, a key feature of our study is that we have also 
provided comparisons between RC and other RDs (i.e. excluding cancer related RDs). Our 
findings show a clear improvement on HRQoL outcomes of RC compared to RD patients, 
highlighting the remaining unmet need in treating RDs as opposed to RCs - for which a 
significant number of therapies exists [23]. More importantly it highlights that rarity of the 
condition targeted by a new therapy itself would not necessarily add true value to the 
respective technology.  This is all the more important when considering that orphan drugs, 
despite being unlikely to demonstrate cost-effectiveness, they are still more likely to receive a 
higher level of acceptance for reimbursement compared to those therapies targeting more 
prevalent conditions.  [24].  
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Finally, another strength of our study is that we compared HRQoL outcomes between highly 
related therapeutic areas in terms of treatment and pathophysiological symptoms. More 
specifically, we observed that RA and MS groups experienced identical burden in terms of 
HSUVs and respective utility losses. Comparable utilities between the two conditions were 
expected since they both belong under the umbrella of autoimmune disorders and both are 
characterized by overlapping Musculoskeletal (MSK) related pathophysiological similarities, 
such as progressive joint damage, daily pain and functional impairment [25]. Nevertheless, 
we also detected discrepancies in HRQoL preferences between RA and MS. Although studies 
show a severe impact of pain on QoL deterioration of MSK disease sufferers [26], our 
findings show that problems with pain were valued differently between RA and MS patients. 
Indeed, evidence from the literature suggests that psychological factors play a major role in 
the pain and disability associated with arthritis [27, 28], while, in contrast, pain and 
anxiety/depression have been repeatedly found to be of less importance for MS cohorts, with 
Mobility typically reported as the most debilitating symptom [29]. Understanding the 
dimensions that are mostly impaired across diseases with pathophysiological similarities and 
hence, often with similar treatments (i.e. Tumor necrosis factorȘ (TNF-Ș) blockers for RA 
and MS [30]) is even more compelling when taking into account the growing trend among 
payers towards value and indication based pricing whereby one product can have different 
prices per indication according to the outcomes it achieves for patient groups across the 
respective indications [24].  
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Limitations and areas for further research 
We demonstrated significant differences in the dimensions that drive HRQoL outcomes 
between rare and more common disease areas and more importantly we showcased that the 
same EQ-5D utility may reflect very different severities depending on the patient population 
under investigation. We believe that the analysis we have presented will be valuable to 
improving future QoL research and Health Technology Assessment processes, as it has 
provided direct comparisons of disease-specific EQ-5D outcomes and hence could inform 
reimbursement decisions on interventions between and within therapeutic areas. However, 
out study is not without limitations. The first limitation relates to sampling issues; due to time 
constraints, a convenience patient sample was drawn, which mostly comprised European-
based patients. In addition, since our survey was only addressed to individuals across a 
limited number of chronic conditions, we acknowledge that, despite the sufficiently large 
overall sample size and the diversity of conditions studied, our results might still not be 
representative of the true magnitude of disease-specific HRQoL differences existing in an 
international population of chronically ill individuals; this can be especially true when 
considering that that the majority of disease areas studied here are predominantly manifested 
in female populations (i.e. BC, RA and MS) and as such resulted in a disproportionately 
higher female population included in our study. Furthermore, the use of a web-survey itself 
raises issues related to the interpretation of the survey questions by the respondents, the levels 
of understanding of the different EQ-5D-5L domains and the respective severity levels 
described. There are also methodological issues associated with the utility and utility loss 
calculations. Firstly, according to table 1, there is an average of 9 years between patients 
diagnosis and the moment they responded to the survey; this implies that for curable 
conditions such as BC and RC, some of the respondents would have already been cured or 
not necessarily receiving treatment at the moment of completing the survey.  
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However, we still considered the contribution of these individuals as important and relevant 
to our research. Due to the effects of cancer and its treatment, cancer survivors often 
experience physical problems such as pain, fatigue, or musculoskeletal problems, even years 
after diagnosis and hence, they have repeatedly been shown to have a reduced physical and 
mental HRQoL compared with general population samples [31].  Nevertheless, to improve 
accuracy of the results a future replication of this research should distinguish between cancer 
survivors (previously treated for cancer) and those that are receiving treatment for cancer at 
the time they are completing the EQ-5D-5L. Secondly, due to time and data constraints utility 
loss calculations were not adjusted for age, gender or other co-morbidities, introducing 
concerns for potential over/under estimation of our findings. As such our findings should be 
interpreted with caution and future replication of the study should take such adjustments into 
account. Thirdly, using UK-specific population norms as a proxy to determine the health 
disutility of participants from countries which had no population norms reported in the 
literature is another limitation in our study. However, as these countries represented less than 
20% of our sample we did not expect this limitation to have a significant impact on the 
overall results. Indeed, a quasi-robustness check (Supplementary Table 2) performed using 
scores from countries that comprised the largest part (nearly 80%) of our sample and for 
which national population norms existed (namely the UK, USA and France) highly reflected 
the findings presented in Table 3, showcasing that regardless of country values used, the 
health states exhibited by individuals in the study disease areas were still differentiated 
following similar patterns. Finally, utilisation of a generic tool such as the EQ-5D has often 
been proven inadequate in capturing a critical domain, which largely shapes QoL outcomes 
in particular disease areas [32]. Therefore, we suggest that future research should also assess 
how patient groups are differentiated based on the outcomes of these key QoL domains not 
included in a generic, preference based tool.  
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Conclusion 
Increasingly stretched health care budgets, and associated challenges in healthcare decision 
making, necessitate that health systems worldwide invest in services and interventions which 
achieve the most meaningful outcomes across disease areas, in the most efficient way. This 
implies that care needs to be tailored such that it would improve those disease specific 
dimensions that would provide the greatest benefit for patients. Despite the limitations of our 
study, the comparisons presented here are worthy of note, since they contribute in our 
understanding of the drivers of impaired HRQoL in one disease area relative to another. 
Ultimately, the findings of these comparisons can be used to inform decisions about the 
optimal allocation of resources based on patient groups with those chronic diseases who are 
in greatest need. Finally, the particular worsening of QoL demonstrated for RDs compared to 
other chronic disease areas, and even more importantly compared to RC highlights that RDs 
still present with significant unmet need in terms of therapies and remain an issue of high 
priority not only for health policy makers and the industry but also for patients and patient 
advocacy groups themselves.  
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Table 1. Sample employment and demographic characteristics 
 
Note: BC=Breast Cancer, RD=Rare Diseases, RC=Rare Cancers, RA=Rheumatoid Arthritis, 
MS=Multiple Sclerosis  
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Table 2. Sample HRQoL characteristics [mean (SD)] and statistical significance (p) of 
differences among disease groups. 
 
Note: BC=Breast Cancer, RD=Rare Diseases, RC=Rare Cancers, RA=Rheumatoid Arthritis, 
MS=Multiple Sclerosis  
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Table 3. Mean scores of EQ-5D-5L domains and EQ-5D-5L HSUV across disease areas and 
statistical significance (p) of differences between RD and other disease areas. 
 
Note: BC=Breast Cancer, RD=Rare Diseases, RC=Rare Cancers, RA=Rheumatoid Arthritis, 
MS=Multiple Sclerosis
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Figure 1. Level of problems reported (%) in each EQ-5D-5L domain across disease areas 
 
Note: BC=Breast Cancer, RD=Rare Diseases, RC=Rare Cancers, RA=Rheumatoid Arthritis, 
MS=Multiple Sclerosis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
